Imugene share price seesaws on 'clarification announcement'

What did Imugene update the ASX with?

| More on:
Two researchers discussing results of a study with each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene shares backtrack 1.58% to 18.7 cents 
  • The company provided further clarification regarding the terminated supply agreement for HER-Vaxx by MSD 
  • Management advised that this will not affect the material cost to the clinical trial 

The Imugene Limited (ASX: IMU) share price is moving in circles during Tuesday afternoon following an update from the company.

At the time of writing, the immuno-oncology company's shares are down 1.58% to 18.7 cents.

It's worth noting that Imugene shares have now lost more than 25% in the past week.

Imugene provides update on terminated supply contract

Investors are continuing to sell off Imugene shares despite the company's clarification announcement made to the ASX today.

According to its release, Imugene advised that the terminated supply agreement by MSD is not a key factors regarding HER-Vaxx. This relates to the technology, clinical trial design, trial data, and the safety of the immunotherapy.

MSD is a tradename of pharmaceutical giant, Merck & Co.

Furthermore, management noted that the study will run as planned with alternate supply arrangements available to the company. This includes direct reimbursement of hospital pharmacies.

Subsequently, Imugene stated that there is no material difference to the cost of the trial as budgeted, or the agreement.

More on HER-Vaxx

HER-Vaxx is a B-cell immunotherapy that has been shown in studies to "stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target."

The immunotherapy is being developed for the treatment of gastric, breast, ovarian, lung and pancreatic cancers.

The primary objective of the upcoming clinical trial is to determine the safety and efficacy of HER-Vaxx in combination with anti-PD-1 therapy.

PD1-Vaxx advantage is that it induces a unique polyclonal immune response that may increase response rates for therapy.

Imugene share price snapshot

Adding to today's fall, the Imugene share price is down 8% over the past 12 months.

However, when looking at year to date, its shares have lost half of their value.

Imugene shares reached an all-time high of 62.5 cents in November, before moving on a downhill trend.

Based on valuation metrics, Imugene has a market capitalisation of roughly $1.09 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »